1093063-68-3

Upstream product

• 1093063-62-7 (S)-3-methylsulfanyl-pyrrolidine-3-carboxylic acid methyl ester L-tartrate 
• 1093063-64-9 (S)-1-(tert-butoxycarbonyl)-3-(methylthio)pyrrolidine-3-carboxylic acid 
• 1093063-63-8 1-(tert-butyl) 3-methyl (S)-3-(methylthio)pyrrolidine-1,3-dicarboxylate 
• 122684-33-7 methyl 1-tert-butoxycarbonyl-3-pyrrolidinecarboxylate 
• 67400-25-3 3-bromo-5-nitro-1H-indazole 
• 1093063-60-5 3-methylsulfanyl-pyrrolidine-3-carboxylic acid methyl ester 
• 942190-28-5 1-(tert-butyl) 3-methyl 3-(methylthio)pyrrolidine-1,3-dicarboxylate 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 1184174-33-1 1-benzyl-3-methylsulfanyl-pyrrolidine-3-carboxylic acid methyl ester 
• 473416-22-7 tert-butyl 3-bromo-5-nitro-1H-indazole-1-carboxylate 
• 5401-94-5 5-nitroindazole 
• 1093063-61-6 methyl (S)-3-(methylthio)pyrrolidine-3-carboxylate 
• 1093063-65-0 C₄₃H₄₁FN₄O₃S 

Downstream Products

• 1093061-47-2 (S)-N-(3-(4-fluorophenyl)-1H-indazol-5-yl)-3-(methylthio)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)ethyl)pyrrolidine-3-carboxamide 
• 1093160-76-9 1-{2-[4-(3-fluoro-4-pyrimidin-2-yl-phenyl)-piperazin-1-yl]-2-oxo-ethyl}-3-methylsulfanyl-pyrrolidine-3-carboxylic acid [3-(4-fluoro-phenyl)-1H-indazol-5-yl]-amide 

Relevant academic research and scientific papers

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology

Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 μM h; F% =

POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER

Disclosed are the ERK inhibitors of formula 1.0: (Chemical formula should be inserted here as it appears on abstract in paper form) and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.